- Home
- SEVN vs PLX Comparison
SEVN vs PLX Comparison
Compare SEVN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SEVN
- PLX
- Stock Information
- Founded
- SEVN 1986
- PLX 1993
- Country
- SEVN United States
- PLX Israel
- Employees
- SEVN N/A
- PLX N/A
- Industry
- SEVN Real Estate Investment Trusts
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SEVN Real Estate
- PLX Health Care
- Exchange
- SEVN Nasdaq
- PLX Nasdaq
- Market Cap
- SEVN 198.5M
- PLX 160.2M
- IPO Year
- SEVN N/A
- PLX 1998
- Fundamental
- Price
- SEVN $12.79
- PLX $2.39
- Analyst Decision
- SEVN Strong Buy
- PLX Strong Buy
- Analyst Count
- SEVN 3
- PLX 1
- Target Price
- SEVN $14.50
- PLX $15.00
- AVG Volume (30 Days)
- SEVN 55.7K
- PLX 646.5K
- Earning Date
- SEVN 02-18-2025
- PLX 03-13-2025
- Dividend Yield
- SEVN 10.95%
- PLX N/A
- EPS Growth
- SEVN N/A
- PLX N/A
- EPS
- SEVN 1.20
- PLX N/A
- Revenue
- SEVN $29,847,000.00
- PLX $45,667,000.00
- Revenue This Year
- SEVN N/A
- PLX N/A
- Revenue Next Year
- SEVN N/A
- PLX $63.84
- P/E Ratio
- SEVN $10.67
- PLX N/A
- Revenue Growth
- SEVN N/A
- PLX N/A
- 52 Week Low
- SEVN $11.83
- PLX $0.82
- 52 Week High
- SEVN $14.66
- PLX $2.76
- Technical
- Relative Strength Index (RSI)
- SEVN 41.55
- PLX 48.43
- Support Level
- SEVN $13.00
- PLX $2.43
- Resistance Level
- SEVN $13.44
- PLX $2.73
- Average True Range (ATR)
- SEVN 0.35
- PLX 0.13
- MACD
- SEVN -0.02
- PLX -0.04
- Stochastic Oscillator
- SEVN 1.52
- PLX 13.95
About SEVN Seven Hills Realty Trust
Seven Hills Realty Trust is a real estate investment trust. The company is engaged in the business of originating and investing in floating rate first mortgage loans secured by the middle market and transitional commercial real estate. Its primary objective is to balance capital preservation with generating risk-adjusted returns.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.